2020-10-02| Funding

Dewpoint Snags Successful Series B to Target Lesser Known Cellular Compartments

by Eduardo Longoria
Share To

By Eduardo Longoria

On September 29th, Dewpoint Therapeutics, the biomolecular condensates company, announced raising US$ 77 million in a Series B round led by ARCH Venture Partners. The round saw participation from new investors Maverick Ventures and Bellco Capital and existing investors Leaps by Bayer, EcoR1 Capital, Polaris Partners, Samsara BioCapital, and Innovation Endeavors. The privately held, small (around 50 employees) and recently founded (2018) firm had its US$ 60 million Series A in early 2019 and is demonstrating strong growth.

Founded by Tony Hyman of the Max Planck Institute in Dresden and Rick Young of the Whitehead Institute, Dewpoint therapeutics, as described on their website, translates condensate biology into much needed medicines. The company, based both in Boston and Dresden, is attempting to develop drugs to hit “undruggable” targets.

Biomolecular condensates are membraneless droplets formed by phase separation inside cells that facilitate molecular interactions and help cells perform vital functions. The condensates are well defined despite being membraneless and act to concentrate and organize biomolecules in areas of the cell that have low concentrations of them. Dewpoint aims to make use of these little studied phenomena to treat and cure rare diseases. The role of the condensates includes cell signaling, immune synapse function, nuclear transcription, RNA splicing and processing, mRNA storage and translation, virus replication, antiviral mechanisms, DNA sensing and protein turnover, and mitosis. Dewpoint also promotes learning about the science behind their products by linking to on their website.

Dewpoint has built a proprietary platform using high-throughput methods to test libraries of potential drugs and identify compounds that modulate biomolecular condensates in specific diseases. Approaches to modulating condensates that may positively impact disease include dissolving or forming condensates, modulating the composition of condensates, stabilizing condensates, and selective drug delivery into condensates.

“Our proprietary platform has already generated two significant external collaborations with Merck and Bayer, and today’s announcement underscores the interest in biomolecular condensates among investors with a track record of backing groundbreaking science,” said Amir Nashat, Interim CEO of Dewpoint Therapeutics.

Dewpoint intends to use the proceeds from this round to develop its platform further and identify additional compounds that modulate their condensates. In particular, Dewpoint focuses on opportunities relating to neurodegeneration, cancer, inflammation, infectious disease, metabolic disease, and rare genetic disorders.

In addition to the financial news, Dewpoint has another reason to be optimistic. Giuseppe Ciaramella, Ph.D., has just been announced as the newest member of Dewpoint’s board of directors. Dr.Ciarmella brings a strong industry background to the job with his experience as president and chief scientific officer of Beam Therapeutics and work at Moderna, AstraZeneca, Boehringer Ingelheim, and Pfizer as well. Dr. Ciaramella holds a B.Sc. and Ph.D. in biochemistry and molecular biology from University College London.

The cutting edge technology and highly skilled personnel of Dewpoint Therapeutics have generated interest from investors and offer them the opportunity to develop treatments for rare and often difficult to treat illnesses and disorders. This traditionally very hard to tap market can turn DewPoint into a giant in its field if its platform becomes as effective as they hope. Becoming the go-to company for a little-studied disorder can guarantee Dewpoint customers and a growing market share for years to come.

Editor: Rajaneesh K. Gopinath, Ph.D.

Related Article: Investors Back Seattle-Based Startup’s Novel Immuno-Oncology Program Targeting Solid Tumors



© All rights reserved. Collaborate with us:
Related Post
Pfizer-backed Flare Taps Caris To Boost Precision Oncology Pipeline
Zenas Picks Up $118 Million To Advance Phase 3 For Autoimmune Candidate
Delfi Diagnostics Amasses $225 Million for Early Cancer Screening
New Regulatory Measures in China A First in the Fight Against Sedentary Behavior in Children
Cure Genetics Announced Promising Safety and Efficacy Data of CAR-NKT Product CGC729 for RCC at ASGCT 2024
AstraZeneca’s $1.5 Billion ADC Manufacturing Facility in Singapore
Hims & Hers Health Inc. Tipping the Scales of the Weight Loss Market — and Wall Street is Loving it!
GV Announces Cooperation with CICC
Eli Lilly and Aktis Oncology Partner to Advance Novel Radiopharmaceuticals
Preventive Medicine for Neurodegeneration on the Rise: New Breakthrough in Routine Blood Testing for Alzheimer’s Disease
Scroll to Top